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Manuscript
  
The study by Mian et al. demonstrates that absence of T regulatory (Treg) cells within 
the T cell population exaggerated Angiotensin II (Ang II)-induced endothelial 
dysfunction, vascular remodeling, oxidative stress and inflammation. The extensive 
work displayed in this manuscript clarifies the protective role of Tregs in vessels and 
highlights how important is to distinguish the different populations of T cells in models 
of disease where chronic inflammation has a key role. The authors corroborate their 
initial hypothesis with exhaustive ex vivo experiments taking into account all the 
possible combinations of T cells transference into T and B cell-deficient recombination-
activating gene 1 knockout (Rag1-/-) mice infused or not with Ang II. The transfer of T 
cells from the Scurfy mouse (Sf), a model which lacks Treg cells because of deficiency 
in the Foxp3 gene, to hypertensive Rag1-/- mice provides an interesting outcome 
regarding the mechanisms underlying the pathophysiology of hypertension and 
confirms the role of natural Tregs in protecting arterial function. 
Emerging evidence from experimental and clinical studies indicates that alterations in 
immune cell populations play an important role in the pathogenesis of cardiovascular 
diseases (1-2). In patients suffering from coronary artery disease (CAD) the ratio 
between effective T cells (Th17) and suppressor T cells (Tregs) is increased due to a 
rise in the number of lymphocytes Th17 and the cytokines related with them, IL17 and 
IL23, and a decrease in the number of Tregs and in the levels of cytokines regulated by 
these, IL10 and TGFβ1 (2). Suppression of the adaptive immune system can attenuate 
hypertension in experimental animals and in humans (3). Moreover, in hypertensive 
patients the Th17 levels are augmented and the neutralization or deletion of IL-17, 
reduces hypertension induced by Ang II (4). In addition, it is reported that immune 
function perturbation by either pharmacological intervention or thymectomy prevented 
hypertension in experimental models (5). Seaberg et al. (6) demonstrated that 
suppression of CD4+ T cells caused by HIV infection is associated with a low incidence 
of hypertension. In rats with established hypertension (SHR), Rodriguez-Iturbe et al. (7) 
showed that intermittent administration of mycophenolate mofetil, a selective 
lymphocyte suppressor agent, reduced the renal inflammatory infiltration and 
hypertension.  
 
The different populations of Tregs share a common characteristic of 
immunosuppressive capability, but differ in their cell surface markers, types, and site of 
formation. Among these populations, natural Tregs, characterized by the expression of 
CD4+CD25+ and the transcription factor (Foxp3) (8), have been well studied and 
accumulating evidence suggests that this population plays a crucial role in the 
maintenance of immunological self-tolerance and negative control of pathological as 
well as physiological immune responses (9). The two cell surface molecules CD4+ and 
CD25+ were used to define this population of Tregs before the identification of the 
transcription factor (Foxp3) expression. Currently, Foxp3 is the most specific molecular 
marker for thymic or peripheral Tregs in rodents and humans. In humans, mutations in 
the gene encoding Foxp3 leads to a severe and fatal autoimmune disorder termed 
immune dysregulation, polyendocrinopathy, enteropathy X-linked (IPEX) syndrome 
(10). Scurfy is an analogous disease that occurs in mice due to a Foxp3 mutation (10). 
Recently, a novel marker for Tregs was identified, the C-type receptor CD69. The 
FoxP3(+)CD69(+) Treg subset is key for immunosuppressive function of Tregs and for 
the maintainance of immune tolerance (11). 
Several groups demonstrated that Tregs are critical in the regulation of arterial blood 
pressure and microvascular function (12-15). In the current work presented by Mian et 
al., the co-transfer of WT-natural Treg cells with Smurfy-T cells (Sf-T cells) delayed 
the onset of Ang II-induced systolic and diastolic blood pressure rise but did not reduce 
the systolic blood pressure after the first week of Ang II infusion. These results are 
controversial since others reported that adoptive transfer of Tregs, freshly isolated from 
normotensive mice, reduced the Ang II-induced BP rise in sustained fashion (12-15). 
This differed from a previous study performed by Kvakan et al. (16) in which, one 
single injection of adoptive Treg cells ameliorated cardiac damage independently of 
blood pressure-lowering effects. However, the dose of Angiotensin II that was used in 
this study was much higher than the doses described in the current and in the above 
mentioned studies. Authors explained this discrepancy by the difference in the Tregs 
injection protocol and by the inflammatory status of T cells. Sf-T cells present a high 
pro-inflammatory status as revealed by analysis of plasma pro-inflammatory cytokines 
and it is known that Tregs number and activity can be modulated positively or 
negatively by several cytokines, with certain cytokines promoting the differentiation 
and function of Tregs, and other cytokines antagonizing those activities (17). This fact 
is reflected in the current study, where the co-injection of Tregs and Sf T cells into the 
Rag1-/- mice could modulate the anti-inflammatory function of the first ones with time. 
However, further studies will be required to determine whether Tregs modulate the 
initiation or maintenance of hypertension. 
Tregs release soluble factors such as IL-10, IL-35, and TGF-β with anti-inflammatory 
properties that may provide vascular protection by a paracrine effect (14, 18, 19). For 
instance, IL-35 has the dual ability to both expand functional Foxp3+IL-10-producing 
regulatory T cells and to suppress Th17 cell differentiation (18). Moreover, the 
suppressive action of Tregs is also exerted on other cell types, such as activated 
monocytes and macrophages (19). In previous studies, it was shown that the transfer of 
Tregs into hypertensive mice decreases inflammation, as evidenced by the reduction in 
inflammatory cytokines and macrophage infiltration into arteries. In this sense, 
Barhoumi et al. (12) reported a decrease in macrophages infiltration in adventitia and 
periadventitial fat after adoptive transfer of Tregs while Kvakan et al. showed that 
adoptive Treg cells transfer resulted in a marked reduction in cardiac CD4+, CD8+, and 
CD69+ cell and macrophage infiltration (16). In the present study, the authors observed 
that loss of Tregs shifted monocyte/macrophage polarization toward M1 while gain of 
Tregs caused the opposite effect in mesenteric arteries and renal cortex suggesting that 
Tregs could modulate the monocyte/macrophage polarization. 
 
In conclusion, the study by Mian et al. demonstrates that specific deficiency of FOXP3-
Tregs exaggerates Ang II-induced resistance artery endothelial dysfunction and 
remodeling, oxidative stress and inflammation, and influences hypertension 
development, by loss of function or gain of function approaches modulating innate and 
adaptive immune responses. The current study has the advantage of investigating both 
Tregs deficiency and replacement as a strategy and it may also be clinically relevant 
because it suggests the positive stimulation of Tregs as one of the critical therapeutic 
targets for preventing microvascular complications associated with hypertension. 
Further elucidation of the interactions between Tregs and the vascular bed by using 
large animal models and human samples is desired and will provide us with a better 
understanding of the roles and the potential interactions of the different T cells 
populations as part of the mechanisms responsible for the progression of cardiovascular 
diseases. 
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